Solaris Endovascular adds Japan and manufacturing leaders

Solaris Endovascular named Eizo Nishimura as general manager for Japan and ZB Briseño Jr. as head of manufacturing as the Dallas-based medtech company pushes global expansion and commercialization. The hires come as Solaris advances its covered stent portfolio, including Solaris SX and the investigational Solaris DE.

Why it matters: - Solaris Endovascular is adding senior leadership in two areas that can shape near-term growth: international commercialization and manufacturing scale-up. - The hires support the company's push to expand outside the United States while advancing its covered stent pipeline. - The move also comes as Solaris works to commercialize Solaris SX globally and develop Solaris DE for dialysis access and peripheral artery disease.

What happened: - Solaris Endovascular appointed Eizo Nishimura as general manager, Japan. - Solaris Endovascular appointed Zaragoza “ZB” Briseño Jr. as head of manufacturing. - The company announced the appointments on September 29, 2026. - The company said the additions strengthen the leadership team as Solaris expands its global presence and advances its covered stent portfolio.

The details: - Nishimura brings more than 40 years of medical device leadership experience in Japan. - At Johnson & Johnson, Nishimura led regulatory approval, reimbursement and commercial launch of CYPHER, the first drug-eluting coronary stent in Japan. - Nishimura later built that business to more than $550 million in annual sales. - Nishimura also served as president and representative director of Biosensors Japan and later Abiomed Japan. - At Abiomed Japan, Nishimura led the introduction of Impella, secured reimbursement and built the Japanese business to more than $75 million in annual revenue. - Briseño brings more than 26 years of medical device manufacturing, operations, process development and scale-up experience. - Briseño’s background includes senior operations leadership at TriSalus Life Sciences. - Briseño also worked with Cordis/J&J on the CYPHER sirolimus-eluting stent, including drug-coating process development, process validation, manufacturing scale-up and global technology transfer. - Solaris said Nishimura’s experience in Japan and Briseño’s manufacturing background will support the company's next phase of growth.

Between the lines: - Solaris is pairing a commercial leader with deep Japan market experience and an operations executive with scale-up credentials. - That combination suggests the company is preparing for broader international execution, not just product development. - The focus on manufacturing leadership also points to the operational demands of moving covered stent technology through commercialization. - The company highlighted recent six-month DEScover results showing 92.7% target lesion primary patency with Solaris DE in failing dialysis access circuits.

What's next: - Solaris will continue commercializing Solaris SX outside the United States. - Solaris will continue advancing clinical development of Solaris DE, which is investigational. - The company expects Solaris DE to address edge restenosis by delivering drug at the uncovered stent edges. - Further progress will likely depend on manufacturing readiness, clinical development and international market execution.

The bottom line: - Solaris is staffing up for global growth while trying to turn its covered stent platform into a broader commercial business.